New York Senate Bill S09659

New York 2025-2026 Regular Session

• Introduced: 3/31/26
• Refer: 3/31/26

Caption

Requires health insurance coverage for home test kits for sexually transmitted diseases.

Summary

This bill would amend New York’s insurance law to require health insurance policies that already cover hospital, surgical, medical, laboratory, or diagnostic X-ray services to also cover home test kits for sexually transmitted diseases. The mandate applies to policies issued by individual, group, and nonprofit health insurers, and it specifically includes tests for STDs such as HIV when the kit is used for self-collection outside of a clinical setting. The bill defines a covered “home test kit” as a product used for a test recommended by CDC guidelines or the U.S. Preventive Services Task Force and that is either CLIA-waived, FDA cleared or approved, or developed by a laboratory under applicable quality standards. Coverage would take effect for policies issued, delivered, renewed, or modified on or after the effective date, which is 90 days after enactment. The bill also authorizes any necessary regulatory changes to be completed before the effective date.

Impact

If enacted, the bill would add a new coverage requirement to sections 3216, 3221, and 4303 of the Insurance Law, affecting individual, small group, large group, and nonprofit health insurance policies in New York. Insurers would need to reimburse or cover eligible at-home STD testing kits, expanding access to remote screening and potentially increasing utilization of preventive sexual health services. The measure would not create a new public program, but it would impose a new mandated benefit on private health plans that already provide medical or laboratory coverage.

Sentiment

No committee transcript or recorded vote is available, so there is no direct evidence of debate or formal support/opposition in the provided materials. Based on the bill’s structure and purpose, the measure appears to be framed as a public health and access-to-care initiative aimed at making STD screening more convenient and accessible. The absence of recorded opposition or amendments suggests no documented controversy in the available record, though the bill has not yet advanced to a stage where broader sentiment can be measured.

Contention

The main policy questions likely concern the cost and administrative burden of adding a new mandated insurance benefit versus the public health benefits of earlier and easier STD detection. Insurers may be concerned about premium impacts, coverage definitions, and whether the mandate could be interpreted broadly enough to include a wide range of at-home diagnostic products. Supporters would likely emphasize access, privacy, and prevention, especially for HIV and other sexually transmitted infections, while any opposition would probably focus on mandate expansion and implementation details rather than the underlying health goal.